Oxurion NV is a company specializing in acquiring majority stakes in promising European pharmaceutical subcontractors. Oxurion NV's ambition is to build an integrated group of subcontractors serving healthcare players. Oxurion NV holds a 72% stake in Axiodis CRO, a subcontractor specialized in biometrics.

Employees

Sector

Biotechnology & Medical Research

Calendar

09-30 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
19/08/26	€0.002800	0.00%	140,414
18/08/26	€0.002800	+16.67%	408,600
17/08/26	€0.002400	-7.69%	250,855
14/08/26	€0.002600	-7.14%	477,627
13/08/26	€0.002800	+7.69%	227,781

Real-time Euronext Bruxelles

More quotes

Income Statement and Estimates

More financial data

Market Closed - Euronext Bruxelles 19:55:00 19/08/2026 +04			5-day change	1st Jan Change
0.002800 ^EUR	0.00%		+7.69%	-61.11%

07-21	Oxurion's Axiodis Partners with KYomed on Clinical Biometrics Services	MT
06-02	Oxurion Positions Itself in the GLP-1 Therapy Market

Market Cap	248K 290K 232K 213K 400K 27.67M 407K 2.74M 1.07M 13.88M 1.09M 1.06M 45.89M	P/E 2024	2.56x	P/E 2025	-0.05x
Enterprise Value	11.26M 13.13M 10.51M 9.65M 18.14M 1.25B 18.44M 124M 48.58M 629M 49.29M 48.22M 2.08B	EV / Sales 2024	3,879x	EV / Sales 2025	20.7x
Free-Float	78.91%	Yield 2024 *	-	Yield 2025	-

07-21	Oxurion's Axiodis Partners with KYomed on Clinical Biometrics Services	MT
06-02	Oxurion Positions Itself in the GLP-1 Therapy Market
06-02	Oxurion Ends Talks to Buy Majority Stake in France-based CRO	MT
04-30	Oxurion NV Auditor Raises 'Going Concern' Doubt	CI
04-30	Oxurion NV Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-19	Oxurion NV signs a letter of intent for acquisition of an International CRO	RE
03-02	Oxurion Extends Talks for Acquisition of Majority Stake in French CRO	MT
01-19	Oxurion Temporarily Suspends Digital Assets Investment Project Amid Crypto Volatility	MT
14/10/25	Oxurion to Acquire Majority Stake in French Contract Research Organization	MT
01/10/25	Oxurion NV Reports Earnings Results for the Half Year Ended June 30, 2025	CI
05/08/25	Oxurion Receives Improved EUR30 Million Indicative Financing Offer from Atlas Special	MT
22/07/25	Oxurion Plans EUR10 Million Bond Issue to Fund Treasury Diversification	MT
22/07/25	Oxurion NV announced that it expects to receive ?10 million in funding from Atlas Special Opportunities LLC	CI

07-21	Oxurion : expands its clinical research platform through strategic biometrics partnership between Axiodis CRO and KYomed INNOV	PU
07-21	Oxurion Nv : Oxurion expands its clinical research platform through strategic biometrics partnership between Axiodis CRO and KYomed INNOV	AT
07-14	Oxurion Nv : Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC	AT
07-06	Oxurion Nv : Oxurion achieves another milestone in the expansion of the Exagis platform with the commercial launch of its eTMF module	AT
06-26	Oxurion Nv : Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC	AT

Oxurion NV Stock

Stocks

OXUR

BE0974487192

Biotechnology & Medical Research

Valuation: Oxurion NV

Chart: Oxurion NV

Latest news : Oxurion NV

Press Releases: Oxurion NV

News in other languages: Oxurion NV

Quotes and Performance

Course Extremes

Managers and Directors: Oxurion NV

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

07-21	Oxurion Nv : Oxurion élargit sa plateforme de recherche clinique grâce à un partenariat stratégique en biométrie entre Axiodis CRO et KYomed INNOV
07-14	Oxurion Nv : Oxurion ontvangt transparantiekennisgeving van Atlas Special Opportunities II LLC
07-08	Oxurion Nv : Informatie met betrekking tot het Totaal Aantal Stemrechten (Noemer) volgend op Atlas Conversie-Notificatie
07-06	Oxurion Nv : Oxurion bereikt een nieuwe mijlpaal in de uitbouw van het Exagis-platform met de commerciële lancering van zijn eTMF-module
07-06	Oxurion Nv : Oxurion franchit une nouvelle étape dans le développement de sa plateforme Exagis avec le lancement commercial de son module eTMF

1 week	+7.69%
Current month	+16.67%
3 months	-26.32%
6 months	-53.33%
Current year	-61.11%

1 week	0		0
1 month	0		0
Current year	0		0.01
1 year	0		0.03
3 years	0		23
5 years	0		25,900
10 years	0		104,600

Manager	Title	Age	Since
Ghoson Pascal CEO	Chief Executive Officer	37	28/12/2023
Philippe Barbeaux CTO	Chief Tech/Sci/R&D Officer	-	28/12/2023
Samuel Darcheville SEC	Corporate Secretary	-	28/12/2023

Director	Title	Age	Since
Ghoson Pascal BRD	Director/Board Member	37	28/12/2023
James Hartmann BRD	Director/Board Member	60	28/12/2023
Charles Paris de Bollardire CHM	Chairman	-	28/12/2023

Date	Insider	Type	Main position	Quantity	% Market Cap.
11/03/22	Ecp Liquid Fund 1 LLC	Buy	Company	1,180	0.0030%
11/03/22	Midelco NV	Buy	Company	1,180	0.0030%
17/11/21	Thomas Clay	Buy	Chairman	2,766	0.0072%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
OXURION NV	0.00%	+7.69%	-88.80%	-99.99%	290K
LONZA GROUP AG	+2.37%	+2.30%	+3.39%	+22.74%	50.5B
REVOLUTION MEDICINES, INC.	-0.62%	+4.58%	+487.47%	+624.71%	46.01B
BEONE MEDICINES AG	+2.09%	+4.96%	+20.59%	+95.21%	42.85B
IQVIA HOLDINGS INC.	+3.85%	+3.13%	+29.60%	+16.50%	41.03B
CELLTRION, INC.	-0.72%	-3.91%	+17.87%	+47.98%	32.02B
MEDPACE HOLDINGS, INC.	+3.04%	+1.89%	+31.62%	+143.62%	16.98B
ASCENDIS PHARMA A/S	+4.33%	+1.63%	-	-	17.05B
EUROFINS SCIENTIFIC SE	+1.44%	+1.52%	+4.22%	+31.00%	14.3B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+3.87%	+1.98%	+82.99%	+45.80%	13.84B
Average	+1.96%	+2.58%	+65.44%	+103.06%	27.46B
Weighted average by Cap.	+1.88%	+2.37%	+104.90%	+154.15%

	2024	2025
Net sales	3K 3.5K 2.8K 2.57K 4.83K 334K 4.91K 33.05K 12.94K 168K 13.13K 12.85K 554K	555K 647K 518K 475K 894K 61.84M 909K 6.12M 2.39M 31.02M 2.43M 2.38M 103M
Net income	119K 139K 111K 102K 192K 13.26M 195K 1.31M 513K 6.65M 521K 510K 21.99M	-3.73M -4.35M -3.48M -3.19M -6.01M -415M -6.1M -41.08M -16.08M -208M -16.32M -15.96M -689M
Net Debt	10.87M 12.67M 10.15M 9.31M 17.52M 1.21B 17.8M 120M 46.91M 608M 47.59M 46.55M 2.01B	11.01M 12.84M 10.28M 9.43M 17.74M 1.23B 18.03M 121M 47.51M 615M 48.2M 47.15M 2.03B